Juvenile Idiopathic Arthritis
📧 Sign up to get email alerts when something new happens for Juvenile Idiopathic Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2024-05-14FDA Approved: XELJANZ — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for XELJANZ (tofacitinib) from Pfizer, granting an additional regulatory action under NDA 213082.
-
CLINICAL_TRIALS research · 2024-05-14Clinical Trial Update: Analysis of Peripheral Blood Lymphocytes in Patients With Juvenile Idiopathic Arthritis With Respect to Disease Subtypes and Therapy
This clinical trial analysis investigates peripheral blood lymphocytes in juvenile idiopathic arthritis patients across disease subtypes and…
-
CLINICAL_TRIALS trial_result · 2024-05-08Clinical Trial Update: Immunogenicity of HPV Vaccine in Immunosuppressed Children [Phase 3]
Phase 3 clinical trial update evaluating immunogenicity of an HPV vaccine in immunosuppressed children with autoimmune diseases, including j…
-
CLINICAL_TRIALS trial_result · 2024-05-03Clinical Trial Update: Drug Compliance and Affecting Factors in Juvenile Idiopathic Arthritis
Completed clinical trial update examining drug adherence and factors influencing compliance in juvenile idiopathic arthritis, including the …
-
FDA approval · 2024-04-30FDA Approved: ABRILADA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
The FDA approved a supplemental application for ABRILADA (adalimumab-afzb) from Pfizer Laboratories Div Pfizer Inc, authorizing its use as a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-04-25Clinical Trial Update: The Reliability and Validity of the Ankylosing Spondylitis Performance Index (ASPI) in Enthesitis-Related Arthritis
This clinical trial evaluates the reliability and validity of the Ankylosing Spondylitis Performance Index (ASPI) in individuals with Enthes…
-
FDA approval · 2024-02-22FDA Approved: ZYMFENTRA — Supplemental Application (CELLTRION USA Inc.)
The FDA approved a supplemental application for ZYMFENTRA (infliximab-dyyb) submitted by Celltrion USA Inc.
-
FDA approval · 2023-12-28FDA Approved: MELOXICAM — Supplemental Application (AiPing Pharmaceutical, Inc)
FDA approved AiPing Pharmaceutical, Inc.'s supplemental application for MELOXICAM (meloxicam).
-
FDA approval · 2023-12-26FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for Renflexis (infliximab) submitted by Organon LLC.
-
CLINICAL_TRIALS trial_result · 2023-12-20Clinical Trial Update: Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population [Phase 4]
Phase 4 clinical trial evaluating intranasal dexmedetomidine for sedation during intra-articular joint injections in children with juvenile …
-
FDA approval · 2023-12-15FDA Approved: HULIO — Supplemental Application (Biocon Biologics Inc)
The FDA approved a supplemental application for HULIO, Biocon Biologics' biosimilar adalimumab (adalimumab-fkJP).
-
FDA approval · 2023-11-21FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals, incorporating changes to the a…
-
FDA approval · 2023-11-03FDA Approved: HUMIRA — Supplemental Application (Cordavis Limited)
FDA approves a supplemental application for HUMIRA (adalimumab) to Cordavis Limited, enabling an additional manufacturing/supply pathway for…
-
FDA approval · 2023-10-18FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)
The FDA approved a supplemental application for Enbrel (etanercept) submitted by Immunex Corporation.
-
FDA approval · 2023-10-06FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2023-09-21FDA Approved: ADALIMUMAB — Supplemental Application (CELLTRION USA, Inc.)
FDA approved a supplemental Biologics License Application for the adalimumab biosimilar ADALIMUMAB-AATY from Celltrion USA, approving its bi…
-
FDA approval · 2023-08-31FDA Approved: TOLMETIN SODIUM — Supplemental Application (Atland Pharmaceuticals, LLC)
The FDA approved a supplemental application for tolmetin sodium from Atland Pharmaceuticals, LLC. This action approves changes under an appr…
-
FDA approval · 2023-07-19FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar of adalimumab from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2023-06-30FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2023-06-14FDA Approved: ABRILADA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for ABRILADA (adalimumab-afzb) submitted by Pfizer Laboratories Div Pfizer Inc to update the labelin…
-
FDA approval · 2023-06-07FDA Approved: MELOXICAM — Original Application (XLCare Pharmaceuticals, Inc.)
The FDA approved the original application for MELOXICAM (meloxicam), a generic version manufactured by XLCare Pharmaceuticals, Inc., under A…
-
CLINICAL_TRIALS trial_result · 2023-05-31Clinical Trial Update: Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients [Phase 2, Phase 3]
Clinical trial update investigating Coenzyme Q10 in Juvenile Idiopathic Arthritis in Phase 2 and Phase 3.
-
FDA approval · 2023-05-23FDA Approved: ADALIMUMAB — Original Application (CELLTRION USA, Inc.)
FDA approved ADALIMUMAB-AATY from CELLTRION USA, Inc. as a biosimilar to adalimumab under an Original Application for the same indications a…
-
FDA approval · 2023-05-18FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar to adalimumab, from QUALLENT PHARMACEUTICALS HEALTH LLC.
-
FDA approval · 2023-05-05FDA Approved: IBUPROFEN — Supplemental Application (Winco Foods, LLC)
The FDA approved a supplemental application for a generic ibuprofen product developed by Winco Foods, LLC.